152 related articles for article (PubMed ID: 33855214)
1. Course of body weight before and after the initiation of insulin therapy in type 2 diabetes mellitus: Retrospective inception cohort study (ZODIAC 58).
Edens MA; van Dijk PR; Hak E; Bilo HJG
Endocrinol Diabetes Metab; 2021 Apr; 4(2):e00212. PubMed ID: 33855214
[TBL] [Abstract][Full Text] [Related]
2. Determinants of excessive weight gain after the initiation of insulin therapy in type 2 diabetes mellitus: Retrospective inception cohort study (ZODIAC 60).
Edens MA; van Dijk PR; Hak E; Bilo HJG
Diabetes Res Clin Pract; 2023 Jun; 200():110719. PubMed ID: 37196706
[TBL] [Abstract][Full Text] [Related]
3. Analysis of glycaemic control and weight change in patients initiated with human or analog insulin in an US ambulatory care setting.
McAdam-Marx C; Bouchard J; Aagren M; Nelson R; Brixner D
Diabetes Obes Metab; 2010 Jan; 12(1):54-64. PubMed ID: 19758356
[TBL] [Abstract][Full Text] [Related]
4. Body weight course in the DIAbetes and LifEstyle Cohort Twente (DIALECT-1)-A 20-year observational study.
Gant CM; Mensink I; Binnenmars SH; van der Palen JAM; Bakker SJL; Navis G; Laverman GD
PLoS One; 2019; 14(6):e0218400. PubMed ID: 31216324
[TBL] [Abstract][Full Text] [Related]
5. Weight gain in insulin-treated patients by body mass index category at treatment initiation: new evidence from real-world data in patients with type 2 diabetes.
Paul SK; Shaw JE; Montvida O; Klein K
Diabetes Obes Metab; 2016 Dec; 18(12):1244-1252. PubMed ID: 27502528
[TBL] [Abstract][Full Text] [Related]
6. Weight gain and insulin requirement in type 2 diabetic patients during the first year after initiating insulin therapy dependent on baseline BMI.
Biesenbach G; Raml A; Alsaraji N
Diabetes Obes Metab; 2006 Nov; 8(6):669-73. PubMed ID: 17026491
[TBL] [Abstract][Full Text] [Related]
7. Weight changes following the initiation of new anti-hyperglycaemic therapies.
Nichols GA; Gomez-Caminero A
Diabetes Obes Metab; 2007 Jan; 9(1):96-102. PubMed ID: 17199724
[TBL] [Abstract][Full Text] [Related]
8. Diabetes-related distress, insulin dose, and age contribute to insulin-associated weight gain in patients with type 2 diabetes: results of a prospective study.
Jansen HJ; Vervoort GM; de Haan AF; Netten PM; de Grauw WJ; Tack CJ
Diabetes Care; 2014 Oct; 37(10):2710-7. PubMed ID: 25011948
[TBL] [Abstract][Full Text] [Related]
9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
10. Patterns of obesity development before the diagnosis of type 2 diabetes: the Whitehall II cohort study.
Vistisen D; Witte DR; Tabák AG; Herder C; Brunner EJ; Kivimäki M; Færch K
PLoS Med; 2014 Feb; 11(2):e1001602. PubMed ID: 24523667
[TBL] [Abstract][Full Text] [Related]
11. Insulin use and weight maintenance in well-controlled type 2 diabetes: a prospective cohort study.
Huizinga MM; Niswender KD; Gebretsadik T; Rothman RL; Shintani AK; Elasy TA
Obesity (Silver Spring); 2008 Aug; 16(8):1933-7. PubMed ID: 18551124
[TBL] [Abstract][Full Text] [Related]
12. Addition of sulphonylurea to metformin does not relevantly change body weight: a prospective observational cohort study (ZODIAC-39).
Schrijnders D; Wever R; Kleefstra N; Houweling ST; van Hateren KJ; de Bock GH; Bilo HJ; Groenier KH; Landman GW
Diabetes Obes Metab; 2016 Oct; 18(10):973-9. PubMed ID: 27265756
[TBL] [Abstract][Full Text] [Related]
13. Glycemic Control and Weight Outcomes for Exenatide Once Weekly Versus Liraglutide in Patients with Type 2 Diabetes: A 1-Year Retrospective Cohort Analysis.
McAdam-Marx C; Nguyen H; Schauerhamer MB; Singhal M; Unni S; Ye X; Cobden D
Clin Ther; 2016 Dec; 38(12):2642-2651. PubMed ID: 27889301
[TBL] [Abstract][Full Text] [Related]
14. Long-term body weight trajectories and metabolic control in type 1 diabetes patients on insulin pump or multiple daily injections: A 10-year retrospective controlled study.
Alderisio A; Bozzetto L; Franco L; Riccardi G; Rivellese AA; Annuzzi G
Nutr Metab Cardiovasc Dis; 2019 Oct; 29(10):1110-1117. PubMed ID: 31371264
[TBL] [Abstract][Full Text] [Related]
15. Insulin initiation in primary care for patients with type 2 diabetes: 3-year follow-up study.
Dale J; Martin S; Gadsby R
Prim Care Diabetes; 2010 Jul; 4(2):85-9. PubMed ID: 20392683
[TBL] [Abstract][Full Text] [Related]
16. Short-term intensive insulin therapy could be the preferred option for new onset Type 2 diabetes mellitus patients with HbA1c > 9.
Weng J
J Diabetes; 2017 Oct; 9(10):890-893. PubMed ID: 28661564
[TBL] [Abstract][Full Text] [Related]
17. Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index.
Raslová K; Tamer SC; Clauson P; Karl D
Clin Drug Investig; 2007; 27(4):279-85. PubMed ID: 17358100
[TBL] [Abstract][Full Text] [Related]
18. Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis.
Pontiroli AE; Miele L; Morabito A
Diabetes Obes Metab; 2011 Nov; 13(11):1008-19. PubMed ID: 21645195
[TBL] [Abstract][Full Text] [Related]
19. Weight gain associated with insulin detemir vs insulin glargine in clinical practice: A retrospective longitudinal cohort study.
Wadsworth TG; Carr GG; Madaras-Kelly K; Remington R; Bell J
Am J Health Syst Pharm; 2021 Feb; 78(5):401-407. PubMed ID: 33354715
[TBL] [Abstract][Full Text] [Related]
20. Changes in Glycemic Control and Body Weight After Initiation of Dapagliflozin or Basal Insulin Supported Oral Therapy in Type 2 Diabetes: A Primary Care Database Study.
Kostev K; Pscherer S; Rist R; Busch S; Scheerer MF
J Diabetes Sci Technol; 2017 May; 11(3):590-596. PubMed ID: 28300454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
